Microbial transformation of danazol with Cunninghamella blakesleeana and anti-cancer activity of danazol and its transformed products
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
Cunninghamella blakesleeana transformed danazol into new metabolites, some of which exhibited anti-cancer activity.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Biotransformation of danazol (1) (17β-hydroxy-17α-pregna-2,4-dien-20-yno-[2,3-d]-isoxazole) with Cunninghamella blakesleeana yielded three new metabolites 2-4 and a known metabolite 5. These metabolites were identified as 14β,17β-dihydroxy-2-(hydroxymethyl)-17α-pregn-4-en-20-yn-3-one (2), 1α,17β-dihydroxy-17α-pregna-2,4-dien-20-yno-[2,3-d]-isoxazole (3), 6β,17β-dihydroxy-17α-pregna-2,4-dien-20-yno-[2,3-d]-isoxazole (4), and 17β-hydroxy-2-(hydroxymethyl)-17α-pregn-1,4-dien-20-yn-3-one (5). Danazol (1) and its derivatives were evaluated against cervical cancer cell line (HeLa). Compound 1 showed a potent cytotoxicity with IC50=0.283±0.013 μM, as compared to doxorubicin (IC50=0.506±0.015 μM), where compound 3 was also found to be significantly active with IC50=13.427±0.819 μM.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Pituitary Gonadotropin Inhibitory Activity of Danazol 1974
- The Treatment of Benign Breast Disease with Danazol 1980
- Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study 2003
- Microbial Transformation of Danazol 2002
Cited by (1)
- Danazol 2022
References (29)
- Microbial Transformation of Danazol via openalex
- Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study via openalex
- Pituitary Gonadotropin Inhibitory Activity of Danazol via openalex
- The Treatment of Benign Breast Disease with Danazol via openalex
- doi:10.1016/j.molcatb.2003.09.012 via openalex
- doi:10.1016/j.tetasy.2009.02.009 via openalex
- doi:10.1016/s0958-1669(00)00142-7 via openalex
- doi:10.1016/j.steroids.2014.01.001 via openalex
- doi:10.1016/s0015-0282(16)46331-4 via openalex
- doi:10.2174/138527210791616786 via openalex
- W2184353134 via openalex
- W2341620185 via openalex
- W4285719527 via openalex
- W6686513504 via openalex
- W6704458832 via openalex
- doi:10.1080/10242420290018069 via openalex
- doi:10.1248/cpb.54.927 via openalex
- doi:10.1016/j.steroids.2014.06.020 via openalex
- doi:10.3906/kim-0912-400 via openalex
- doi:10.1016/j.steroids.2011.06.007 via openalex
- doi:10.1016/j.molcatb.2010.09.001 via openalex
- doi:10.1093/oxfordjournals.annonc.a010717 via openalex
- doi:10.1023/a:1015905832184 via openalex
- doi:10.3109/14756366.2011.590804 via openalex
- doi:10.1186/1477-7827-3-38 via openalex
- doi:10.1038/nrc706 via openalex
- doi:10.1002/cbdv.200590019 via openalex
- doi:10.1046/j.1525-1373.1999.d01-122.x via openalex
- doi:10.1016/j.steroids.2010.05.017 via openalex
Cited by (1)
- Danazol 2022
Source provenance
- openalex
- last seen: 2026-05-11T06:09:19.794676+00:00
- unpaywall
- last seen: 2026-09-26T06:30:31.687879+00:00
License: CC0
· commercial use OK